- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 24
- States / cities
- Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus
- Interventions
- LINjeta U-100 Insulin, Humalog U-100
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Stanford, California • Denver, Colorado
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- IIM System, Insulin Lispro and/or Insulin Glargine
- Device · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Mellitus
- Interventions
- VGo
- Device
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Macon, Georgia
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Insulin Lispro (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 99
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
- Conditions
- Safety and Tolerability
- Interventions
- inhaled human insulin, Insulin Lispro (Humalog U-100)
- Drug
- Lead sponsor
- Dance Biopharm Inc.
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
- Interventions
- Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
- Drug · Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California